ClinicalTrials.gg
CompletedNCT06680674DiabesityDayUpdated Oct 7, 2026

Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

An observational study in Diabetes Mellitus and Obesity, sponsored by Medical University of Vienna. Completed at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Medical University of Vienna · Observational

How we know

Updated Oct 7, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
207
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diabetes Mellitus by Medical University of Vienna — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus · Medical University of Vienna.

Started
2024
the only one that year
Observational
3 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Diabetes Mellitus by Medical University of Vienna, this one is the only one that started in 2024, is one of 3 observational ones, and was the 12th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 13 studies in Diabetes Mellitus by Medical University of Vienna is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Medical University of Vienna, or all of them as a file.
02

Study summary

Diabetes related to obesity ("diabesity") is becoming increasingly prevalent. Hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays.

However, the pharmacological treatment of diabesity has made significant progress in recent years.

The objective of this study is to assess the management of diabesity in the international hospital setting. Aims include:

  1. to determine the prevalence of causes and duration of hospitalization
  2. to investigate the treatments used
  3. to determine individual metabolic control achived This is a cross-sectional multi-centre study in which researchers will conduct a one-day point prevalence assessment in internal medicine wards.
03

Conditions studied

  • Diabetes Mellitus
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (age ≥ 18 years) with diabetes who are admitted to an internal medicine ward of a participating medical centre at the time of the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized at the time of the survey for any cause
  • Diabetes diagnosis (Known / documented in medical history or newly diagnosed using ADA diagnostic criteria)
  • Age ≥ 18 years
  • Written

Exclusion criteria

Exclusion Criteria:

  • Patients in wards and units other than internal medicine wards (such as outpatient areas, emergency departments, skilled nursing and intensive care units, etc.)
  • Paediatric patients (Age \< 18 years)
  • Patients without a diabetes diagnosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
207 participants (actual)
Patient registry
No

Interventions

  • OtherRoutine care for people with diabetes, with or without obesity, in the hospital setting

    Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.

06

What researchers measure

Primary outcomes

  1. Number of point-of-care glucose values

    Mean number of point-of-care glucose measurements during hospitalization

    Time frame: 3 days

Secondary outcomes

  1. Severe hypoglycaemia

    Severe hypoglycaemia during admission (glucose \<40mg/dL)

    Time frame: From day of admission to the day of data collection, i.e., November 14, 2024

Other outcomes

  1. Diabetes treatment during hospitalization

    Diabetes treatment used during the time of hospitalization

    Time frame: From day of admission to the day of data collection, i.e., November 14, 2024

  2. Insulin regimen during hospitalization

    Insulin regimen used during the time of hospitalization (e.g., correction, basal, prandial bolus)

    Time frame: From day of admission to the day of data collection, i.e., November 14, 2024

07

Study locations

8 sites
  • Medical University of Vienna
    Vienna, State of Vienna 1090, Austria
  • General University Hospital in Prague
    Prague, Czechia
  • University Hospital RWTH Aachen
    Aachen, Germany
  • Hippokration General Hospital, Aristotle University of Thessaloniki
    Thessaloniki, Greece
  • Rabin Medical Center, Hasharon Hospital
    Petah Tikva, Israel
  • Riga East Clinical University Hospital
    Riga, Latvia
  • Rostov State Medical University
    Rostov-on-Don, Russia
  • Kanuni Sultan Suleyman Training and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Patient data will only be shared in aggregated form.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Mar 2025, 4 months.

Completion moved once since we started tracking on Sep 25, 2026: May 2025 → Sep 2025, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Nov 13, 2024
Primary completionActual
Mar 25, 2025
CompletionActual
Sep 2, 2025was May 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Sites
1 site added, 1 site removed
Show site
  • Medical University of Vienna · Vienna, Austria
Show 1 removed
  • Medical University of Vienna · Vienna, Austria
Oct 7, 2026
Primary completion
Mar 18, 2025→Mar 25, 2025
Oct 7, 2026
Study completion
May 31, 2025→Sep 2, 2025 (actual)
Oct 7, 2026
Enrollment
400 (estimated)→207 (actual)
Oct 7, 2026
Sponsor
Collaborators added: Complejo Hospitalario de Especialidades Juan Ramón Jimenez; collaborators removed: Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Medical University of Vienna · Vienna, Austria
    Show 1 removed
    • Medical University of Vienna · Vienna, Austria
    Primary completion Mar 18, 2025→Mar 25, 2025
    Study completion May 31, 2025→Sep 2, 2025 (now actual)
    Enrollment 400 (estimated)→207 (actual)
    Sponsor Collaborators added: Complejo Hospitalario de Especialidades Juan Ramón Jimenez; collaborators removed: Complejo Hospitalario de Especialidades Juan Ramón Jimenez
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06680674
Collaborators
Hospital de Cascais Dr. José de Almeida (Portugal), Centre Hospitalier Universitaire Sétif, Service Médecine Interne (Algeria), Rabin Medical Center, Hospital Regional de Malaga, Charles University, Czech Republic, University Hospital Bratislava, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Medical University Innsbruck, Aristotle University Of Thessaloniki, Rostov State Medical University, Hospital Marina Baixa, Riga East Clinical University Hospital, University Hospital, Aachen, San Raffaele University Hospital, Italy, Kanuni Sultan Suleyman Training and Research Hospital
Responsible party
Ann-Kristin Porth (Research Assistant (PhD), Medical University of Vienna) — Principal investigator
First posted
Nov 8, 2024
Start date
Nov 13, 2024
Primary completion
Mar 25, 2025
Completion
Sep 2, 2025
Last update
Oct 7, 2026

Study contacts

Alexandra Kautzky-Willer, Prof
study director · Medical University of Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion